For the systematic review — published in the journal Pediatrics — researchers analyzed studies published from 1946 to 2016 compiled in the Medline and Embase databases. A total of 68 studies met criteria for inclusion. Among these studies, just 46 enrolled a comparison group that had not been exposed to opioids, 30 performed statistical tests to quantify the association between prenatal opioid exposure and congenital birth defects, and 17 total studies identified a correlation between opioids and birth defects.
“Uncertainty remains regarding the teratogenicity of opioids,” concluded the study’s authors. “A careful assessment of risks and benefits is warranted when considering opioid treatment for women of reproductive age.”
More articles on opioids:
FDA commissioner establishes new opioid committee
Poll: 1 in 3 millennials know someone addicted to opioids
Barnesville Hospital launches addiction services to curb drug overdoses
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
